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Abstract.  We studied the immunocytochemical local- 
ization of urokinase-type plasminogen activator (u-PA) 
and the type 1 plasminogen activator inhibitor (PAI-1) 
in human fibroblasts and sarcoma cells, using both 
polyclonal and monoclonal antibodies.  The u-PA was 
found to be located at discrete cell-substratum contact 
sites, and also at areas of cell-cell contacts, whereas 
PAI-1 was distributed as a homogenous carpet exclud- 
ing strialike areas on the substrate under the cells.  To 
confirm the extracellular localization of u-PA and PAI- 
l,  we stained the cells live at 0°C before fixation. 
A  double-labeling experiment showed different distri- 
bution of u-PA and PAI-1 under the cells, and espe- 
cially their peripheral parts.  The staining pattern of 
u-PA and PAI-1 resisted treatment with 0.2%  saponin 
followed by mechanical removal of cells, a method 
previously reported to isolate focal contact membranes 
of fibroblasts. We further demonstrated the deposition 
of u-PA to the contact areas of cells obtained by sapo- 
nin treatment by zymography, and that of PAI-1 by 
metabolic labeling,  reverse zymography, immunoblot- 
ting,  and immunoprecipitation.  Fibronectin was also 
present in the preparations.  The deposition of both 
PAI-1 and fibronectin by the sarcoma cells was en- 
hanced,  after treating the cells with  10  -6 M  dexametha- 
sone. The confinement of u-PA to discrete contact sites 
and the more uniform distribution of PAI-1 on the cell 
substratum may explain how cells producing large 
amounts of enzyme inhibitors can produce PA- 
mediated focal proteolysis. 
p 
LASMINOGErq activators (PAs)  ~ are serine proteinases, 
which by limited proteolysis convert the abundant ex- 
tracellular  proenzyme plasminogen  into  the  active 
proteinase  plasmin.  Two different  types of PAs have been 
recognized in mammalian  tissues: the urokinase type (u-PA) 
and the tissue type (t-PA), with approximate  Mr 50,000 and 
70,000, respectively.  Evidence has  accumulated indicating 
that u-PA plays a role in tissue degradation both in the normal 
organism and in cancer, whereas t-PA is supposed to be a key 
enzyme in thrombolysis (for reviews see references  12,  13, 
16, 46, 58, 59). 
Several of the plasma proteinase  inhibitors  interact  with 
PAs. Specific protein inhibitors  of PA have also been identi- 
fied in a number of tissues, body fluids, and cell cultures (10, 
14, 18, 19, 22, 26, 30, 35, 42, 44, 56, 66, 70, 73, 78, 80, 81, 
83), though the mutual relationship  of these inhibitors is not 
yet fully clarified.  An Mr 54,000 plasminogen  activator  in- 
hibitor (PAI) was recently purified from the human fibrosar- 
coma cell line HT-1080 (4), and immunologic  evidence sug- 
1. Abbreviations  used in this paper: HES, human embryonic skin; PA, plas- 
minogen activator; PAl, PAl-l, or PAl-2, plasminogen activator inhibitor, 
or specifically, PAl type 1 or type 2; t-PA, tissue-type plasminogen activa- 
tor; u-PA, urokinase-type plasminogen activator;  TNP, trinitrophenyl. 
gested that it is of the same type as the inhibitors  from the 
rat hepatoma cell line HTC (66), bovine endothelial cells (18, 
42, 44, 56, 70), and human blood platelets (19). This inhibi- 
tor has been designated plasminogen  activator  type 1 (PAI- 
l).2 Other types of inhibitors  acting on plasminogen  activa- 
tors include the protease nexin I (33, 64, 65) and that present 
in human  placenta  (PAI-2) (26, 30,  83). 
Plasmin  has  a relatively  broad specificity, being able to 
degrade known extracellular  matrix glycoproteins and to ac- 
tivate latent  collagenase  (52, 54, 60). The affinity of plas- 
minogen and plasminogen  activators for laminin (61), fibro- 
nectin (62),  and fibrin (45) further suggests the importance 
of these proteinases in the turnover  of matrix  components. 
Clearly,  proteolysis taking  place at cellular contact sites is 
of considerable importance for the interaction  between the 
membrane structures  and the surrounding  matrix  compo- 
nents. Proteolytic targets of the pericellular matrices of cells 
in culture have been reported to include fibronectin (74) and 
an Mr 66,000 matrix-associated  protein (31), which seems to 
be a plasminogen-independent  cellular target  for u-PA. In 
2.  Nomenclature recommended by the Subcommittee on Fibrinolysis of the 
International Committee on Thrombosis and Hemostasis,  8 June  1986; 
Kruithof,  E. K.  O., personal communication. 
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the focal degradation of fibronectin substrate by Rous sar- 
coma virus-transformed chicken and rat cells (11). 
We now report that u-PA is located at cell-substratum and 
cell-ceU contact sites of cultured human fibroblasts and sar- 
coma cells, whereas a specific Mr 54,000 PAI is homogene- 
ously distributed on the substrate under the cells. 
Materials and Methods 
Cell Cultures 
The human fibrosarcoma cell line HT-1080 was obtained from the American 
Type Culture Collection (CCL 121, Rockville, MD). The human embryonic 
skin fibroblast cultures (2-HES) were established locally by conventional 
methods and were used at the 10-20 passage level. The ceils were grown 
either in plastic petri dishes (53 cm  2) or in plastic Linbro wells (2 cm2; 
How Laboratories, Inc., McLean, VA) in Eagle's minimal essential medium 
(MEM)  supplemented with  10%  fetal calf serum  (Gibco, Grand Island, 
NY),  100 IU/ml penicillin, and 50 ~tg/ml streptomycin. Cells were plated 
onto glass coverslips 24 h before extraction (see below). 
Contact Area Preparations 
Two procedures for removal of cells were used to prepare samples for im- 
munofluorescence microscopic observations. Method I consisted of wash- 
ing the cell layers at 0°C three times with PBS (10 mM NaPO4, 145 mM 
NaCl, pH 7.4). The cultures were then placed in PBS supplemented with 
0.2% saponin (white; BDH Chemicals Ltd., Poole, England) and shaken 
for 20 rain at 0°C on a rotary shaker at 100 rpm. Then the coverslips were 
intensively pipetted in PBS and the material remaining bound to coverslips 
was fixed for 20 min in 3 % (wt/vol) paraformaldehyde, prepared in buffered 
saline. In method H, instead of saponin, the cultures were incubated over- 
night in cold PBS, thereby letting the ceils detach from the coverslips more 
slowly. In the morning the cultures were pipetted and washed in PBS and 
fixed as in method I. 
Methods I and II were applied when the proteins remaining associated 
with the coverslip were to be analyzed. Cells were seeded onto Linbro wells, 
each well containing one coverslip. After a 24-h incubation at 37°C the 
medium was changed into serum-free MEM lacking methionine, and the 
cultures were further incubated for 2 h. The cultures were then metaboli- 
cally labeled for 2 h with 50 lxCi/ml [35S]methionine  (Amersham Interna- 
tional, Buckinghamshire, England). The extraction procedure was carried 
out as detailed above (methods I and 11). After excess buffer had been 
drained and removed by aspiration, the material remaining attached to the 
coverslips vats dissolved at 0*C in Laemmli's sample buffer (1.25 M Tris- 
HCt, pH 6.8, containing 4% SDS, 20% glycerol, 0.005% bromphenol blue, 
and  in reduced samples  10%  2-mercaptocthanol).  The reduced  samples 
were heated at 100°C for 2 min. Methods I and II gave quantitatively similar 
results. 
Dexamethasone Treatment 
Dexamethasone (Sigma Chemical Co., St. Louis, MO) was diluted from 
ethanol-based stock solution. The final dexamethasone concentration in the 
culture medium was 10  .-6 M. 
Immunofluorescence 
Polyclonal purified rabbit IgG and monoclonal (clone 12) mouse antibodies 
against u-PA, and mouse monoclonal (clone 1) and affinity-purified poly- 
clonal rabbit IgG antibodies against PAl-1 from the HT-1080 cell line were 
prepared  as described  elsewhere  (4,  34,  49,  50).  Monoclonal antibody 
against the trinitrophenyl group, anti-TNP-IgG, was from the hybridoma 
clone designated Hy 2.15 (63). Rabbit antisera to flbronectin (25) and lami- 
nin (1) were produced and their specificity characterized as described. Mu- 
rine monoclonal antibody fpg-9 to fibronectin was raised and its specificity 
in  solid-phase  radioimmunoassay, enzyme  immunoassay, and  immuno- 
blotting established in collaboration with Drs. S. Barlati, V. Miggiano, and 
T. Vartio, as described elsewhere for monoclonal antifibronectin antibodies 
of the same series (76, 77). Rabbit antibodies to vinculin were from a com- 
mercial source (Transformation Research Inc., Framingham,  MA). Fluo- 
rescein isothiocyanate (FITC)-conjugated sheep anti-rabbit immunoglobu- 
lin was from Wellcome (Beckenham, England) and tetramethylrhodamine 
isothiocyanate (TRITC)-conjugated goat anti-mouse immunoglobulins were 
from Nordic Immunological Laboratories (Tilburg, The Netherlands). 
For immunofluorescent staining, coverslip cultures of cells were washed 
three times with cold PBS and fixed with either  -20°C methanol or 3% 
(wt/vol) paraformaldehyde for 20 min. The intracellular antigens were ex- 
posed by detergent treatment (0.1% Triton X-IO0). The procedures for prep- 
aration of cellular contact areas have been detailed above. After additional 
washes with PBS the coverslips were incubated with the primary antibodies 
at a concentration of 50 I~g/ml (antibodies to u-PA and the Mr 54,000 in- 
hibitor) or diluted 1:100 (rabbit antifibronectin, rabbit antilaminin, and an- 
tivinculin sera) or 1:30 (monoclonal fpg-9 antifibronectin ascites) for 30 
min. This was followed by a short rinse in PBS and incubation with fluoro- 
chrome  (FITC/TRITC)-conjugated  anti-rabbit/mouse  immunoglobulins 
diluted 1:40 for 30 min. Staining of live cells was carded out at 0°C and 
consisted of incubation with the primary antibody prior to fixation with 
o  -20 C methanol and incubation with the fluorochrome-conjugated second- 
ary antibody. For double-immunofluorescence studies of  u-PA or PAl-l, the 
cells  were  incubated with  antibodies  in  the following sequence:  rabbit 
anti-u-PA IgG, sheep anti-rabbit  immtmoglobulins (FITC),  mouse anti- 
PAl-1 clone 1, goat anti-mouse immunoglobulins (TRITC). Immunocyto- 
chemical controls included incubation with polyclonal antibodies preab- 
sorbed with either highly purified u-PA (34) or PAl-I, and with preimmune 
rabbit IgG or mouse monoclonal anti-TNP-IgG, and omission of one of  the 
steps in the staining procedure. After washing with PBS the coverslips were 
mounted in a solution consisting of glycerol and PBS in a one-to-one ratio. 
The specimens were viewed with a Leitz Dialux 20 EB microscope (E. Leitz, 
Wetzlar, Federal Republic of Germany)  with epi-illumination.  The light 
source was an HBO 200 high pressure mercury lamp and filter blocks 12 
(excitation 450-490  nm, cutoff 515  nm) and N  (excitation 530-560  nm, 
cutoff 580 nm) for FITC and TRITC, respectively, were used. 
Immunoelectron Microscopy 
The Linbro wells with cells were briefly rinsed three times with Dulbecco's 
PBS (DPBS) containing 0.2% BSA at 0°C, and then incubated with the pri- 
mary antibody for 30 min, the entire experiment being made at 0°C. After 
rinsing three times with DPBS +  0.2% BSA, the cells were fixed with 1% 
glutaraldebyde (Sigma Chemical Co.) in 0.1 M phosphate buffer, pH 7.2, 
for 20 min, followed by treatment with 5 mg/ml NaBI-h in the same phos- 
phate buffer for 30 min. The cells were washed then three times with DPBS 
+  0.2% BSA, and then incubated with Perox Aflini pure goat anti-rabbit 
IgG (H&L, Jackson Immuno Research Laboratories Inc., Avondale, PA) 
o  diluted 1:30 in DPBS + 0.2 % BSA at 0 C for 30 min, and washed thereafter 
five more times. The peroxidase-catalyzed staining reaction was performed 
with the following mixture: 0.05 % diaminobenzidine (Sigma Chemical Co.) 
and 0.001% H202 in 0.05 M Tris-HCl buffer, pH 7.6. After a 10-min stain- 
ing, the cells were briefly rinsed three times with PBS, and postfixed with 
1.5% OsO4 in 0.1 M cacodylate buffer, pH 7.2, for 1 h at room tempera- 
ture, and dehydrated with ethanol. The wells were mounted in Epon 812. 
After polymerization for 2 d, the Epon blocks were sectioned vertically 
against the cell layer. Thin sections (about 80 nm) were observed in a Jeol 
100 CX TEMSCAN electron microscope at 40.0 kV at the Department of 
Electron Microscopy, University of Helsinki,  Finland. 
Polyacrylamide Gel Electrophoresis (PAGE) 
and Immunoblotting 
Preparation and electrophoresis of samples in 8 % and 5-16  % gradient SDS 
polyacrylamide slab gels were as described by Laemmli (36). Radiolabeled 
material was detected by fluorography. Immunoblotting of proteins trans- 
ferred electrophoretically to nitrocellulose sheets (type HAWP filter; Milli- 
Figure 1. Immunofluorescence localization of u-PA and fibronectin in cultured human HT-1080  sarcoma cells and 2-HES fibroblasts. (A, 
C, and F) HT-1080,  methanol fixation; (E) 2-HES, methanol; (B, D, and G) HT-1080,  cells removed using the saponin procedure. The 
cells in G were cultured in the presence of 10-~M dexamethasone. Primary antibodies: polyclonal anti-u-PA (A-C and E), monoclonal 
clone 12 anti-u-PA (D), polyclonal anti-u-PA absorbed with purified u-PA (F) and monoclonal fpg-9 anti-fibronectin (G).  Indirect im- 
munofluorescence and anti-rabbit IgG FITC (A-C, E, and F), and anti-mouse IgG TRITC  (D and G) were used. Bars,  10  ~tm. 
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ing according to Towbin et al. (72) as modified (75). Commercially available 
low  molecular weight markers  (Pharmacia  Uppsala,  Sweden) and  ~C- 
labeled markers (Amersham International) were used. 
Zymography 
The contact area preparations were analyzed for PA activity as described 
previously (23). Briefly, after electrophoresis  in an 8 % polyacrylamide slab 
gel under nonreducing conditions and without heating the specimen, SDS 
was removed from the gels with extensive washing on a gyratory shaker for 
6 h in PBS with 2.5 % Triton X-100, and an indicator agarose gel containing 
casein and plasminogen was placed in contact with the polyacrylamide gel. 
An agarose gel lacking plasminogen was used as a control. To determine 
the type of  the PA activity, contact area preparations were dissolved in 0.5 % 
Tri~n-X-100 and run through a column of Sepharose-coupled monoclonal 
anti-u-PA or anti-t-PA before running the specimens in SDS PAGE.  PAIs 
in polyacrylamide gels were detected by washing the gel first in the same 
solution as above, but containing 50 IU of u-PA in 100 mi of washing solu- 
tion (Calbiochem Behring Corp., La Julia,  CA). When layered over an 
agarose gel containing casein and plasminogen, a general lysis of the casein 
took place except where inhibitors were present in the polyacrylamide gels. 
These positions were  revealed by  opaque lysis-resistant zones:  reverse 
zymography (20). 
u-PA and PAI-1 Preparations 
u-PA was from a commercial preparation (Mr 54,000,  60,000  IU/mg, Cal- 
biochem). PAI-1 was purified from conditioned culture medium of dexa- 
methasone-treated HT-1080 cells as described in detail elsewhere (4). Iodi- 
nation of u-PA and PAI-1 was carded out with the Iodo-Gen method (Pierce 
Chemical Co., Rockford, IL). 
Immunoprecipitation 
For the immunoprecipitation experiment, metabolically labeled cells were 
extracted using method I (see above), the contact area material being dis- 
solved in 500 Ixl of 0.1% (wt/vol) SDS, 0.5% (vol/vol) Triton X-U4, 50 mM 
Tris-HCI buffer, pH 8.0, 150 mM NaC1. 70 ~tl of 10% (wt/vol) solution of 
washed Protein A-Sepharose  CL-4D beads (Pharmacia) in 50 mM Tris-HCl 
buffer, pH 8.0, 150 mM NaCI was added, and after 15 min beads were sep- 
arated by centrifugation at 9,000 g for 1 min. 5 lxl of the monoclonal anti- 
body against PAI-I  was added to the supernatant, and the mixture was in- 
cubated overnight at 4°C. The samples were further incubated with Protein 
A-Sepharose beads as above for 60 min at 37"C in an end-over mixer. The 
precipitate was washed four times with the dissolving buffer and once with 
50 mM Tris-HC1, pH 8.0, 150 mM NaCI, before resolvement by SDS PAGE 
on 8 % acrylamide gels. The dried gels were exposed on to Kodak XAR-5 
film for autoradiography. 
Conversion of  AddedU~I-u-PA to a High Molecular 
Mass Form in Contact Area Preparations 
~2SI-u-PA prepared as described above and diluted in PBS (106 cpm/ml), 
was added to freshly prepared contact area material of 2-HES fibroblasts 
obtained by saponin treatment as described. After incubation for 60 min at 
4°C the preparations were washed with PBS, and the bound proteins were 
dissolved in Laemmli's sample buffer under nonreducing conditions, and 
analyzed in SDS PAGE followed by autoradiography. 
Results 
lmmunocytochemical Localization of  u-PA and PAI-1 
HT-1080 and 2-HES cells were grown on glass coverslips 
overnight. After rinsing with ice-cold PBS, the cells were 
fixed or removed either by treating them with 0.2% saponin 
or by letting them shed overnight in PBS at 4°C as described 
in Materials and Methods. The fixed cells and the material 
remaining on the coverslips were examined by immunofluo- 
rescence microscopy. 
Using both a polyclonal and a monoclonal antibody we 
found u-PA to be located at cell substratum contact sites of 
HT-1080 fibrosarcoma cells. Staining was also detectable in 
areas of cell-cell contacts (Fig.  1, A and C).  The label as- 
sociated with the substratum resisted the saponin extraction 
procedure, making the footprint contact pattern of immuno- 
fluorescence even more evident (Fig. 1, B and D). When live 
HT-1080 cells were stained, we detected patches of staining 
at cell-cell contacts and a weak diffuse pattern of immuno- 
fluorescence over the dorsal surfaces of cells (see Fig. 4 A), 
in addition to that in the contact sites on the substratum (see 
Fig. 4 B). These results demonstrate the extracellular loca- 
tion of the u-PA antigen. Intracellular anti-u-PA staining was 
also seen, showing highest intensity in the perinuclear region 
(Fig. 1, A and C). This was particularly the case, when cells 
were fixed with paraformaldehyde followed by various per- 
meabilization procedures (not shown). At the electron mi- 
croscopic level we could observe patches of polyclonal anti- 
u-PA staining extracellularly in association with the plasma 
membrane. Occasionally, a patch of stain formed a contact 
between two neighboring HT-1080 cells (Fig. 2 A). Human 
fibroblasts showed much lower staining intensity for u-PA 
than sarcoma cells. Only rarely were we able to detect a con- 
tact site staining pattern similar to that visualized in Fig. 1 E. 
Staining with a monoclonal antibody to PAI-1 gave a simi- 
lar pattern in fibrosarcoma cells and in fibroblasts. The im- 
munofluorescence  consisted of  a homogeneously layer on the 
substratum. There was also intracellular perinuclear staining 
with very intensive labeling, presumably indicating PAl-1 
synthesis (Fig. 3, A and B). After saponin extraction of  cells, 
the immunofluorescence consisted of a homogenous carpet 
in the cell peripheral area interrupted by striae of negative 
staining (Fig. 3 C and D), which were also very faintly pres- 
ent  in  cells  fixed with  -20°C  methanol  (see  Fig.  5  A). 
Affinity-purified polyclonal rabbit anti-PAi-I IgG gave simi- 
lar  staining  patterns as the monoclonal antibody.  In cells 
stained live at 0°C with anti-PAI-1 antibodies, the immuno- 
fluorescence was restricted to the peripheral parts of the cells 
whereas the central areas appeared negative (Fig. 4 C). We 
interpret this to be the result of antigen in accessibility on the 
substrate under live cells in that the antigen was seen in the 
saponin-treated preparation on the substratum (Fig. 3, C and 
D). Double-stained HT-1080 cells, featured in Fig. 5, A and 
B, show that u-PA and PAI-1 have distinct staining patterns 
especially on the peripheral parts of the cells. 
Fibronectin was detected with a polyclonal and the fpg-9 
monoclonal antibody in both cell lines. The saponin contact 
preparations of  fibroblasts displayed a typical matrix pattern, 
whereas in HT-1080 preparations the corresponding pattern 
was dominated by dots and striae. Fig.  1 G shows the fpg-9 
staining pattern in a contact area preparation of dexametha- 
sone treated HT-1080 cells. Neither HT-1080 nor fibroblast 
contact preparations displayed vinculin or laminin, as inves- 
tigated by immunofluorescence using polyclonal antibodies. 
Specificity controls including the use of up to 50 ~tg/ml 
preimmune IgG corresponding to the anti-u-PA or anti-PAI- 
l  and monoclonal anti-TNP-IgG were negative, as were ex- 
periments in which one of the steps in the staining protocol 
was omitted (Fig. 2 B). Absorption of the antibodies with 
either highly purified u-PA (Fig.  1 F) or PAl-1 (not shown) 
completely abolished the staining described above. 
psS]Methionine Labeling and Immunoprecipitation 
To characterize the macromolecular components of the con- 
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croscopic localization of u-PA 
in cultured  HT-1080 sarcoma 
cells.  The  cells  were  incu- 
bated  with  the  primary anti- 
body  (polyclonal  anti-u-PA, 
A; none, B) at 0°C before fix- 
ation with glutaraldehyde and 
subsequent  incubation  with 
NaBI4_4.  Peroxidase-conjugated 
anti-rabbit IgG was  used  as 
the second antibody. The en- 
tire  experiment  was  carried 
out at 0°C. Note the extracel- 
lular patches of the antigen on 
the  cell  surface  and between 
cells.  Bars, 0.2 ttm. 
tact area preparations obtained by method I, we labeled the 
cells metabolically with [35S]methionine  in the presence or 
absence of 10  -6 M  dexamethasone in the culture medium. 
The material attached to the glass coverslip was analyzed in 
SDS-PAGE followed by autoradiography.  One major band 
run at Mr 54,000 and coelectrophoresed with purified radio- 
labeled PAI-1 (Fig. 6, lane 5) in HT-1080 as well as fibroblast 
contact preparations.  The monoclonal anti-PAI-1 antibody 
also immunoprecipitated a similar band from the preparation 
(see Fig.  10). However, the precipitation of PAI-1 did not re- 
suit in a quantitative depletion of the Mr 54,000 band from 
the immune supernatant.  Thus,  it cannot be excluded that 
there are at least two Mr 54,000 proteins comigrating in the 
metabolically labeled contact area preparation. Enriched in 
the contact area preparations were also bands at Mr 60,000, 
75,000,  and 250,000.  Dexamethasone in the culture medium 
increased the intensity of the Mr 54,000 and 250,000 bands 
on the HT-1080  contact preparations (Fig.  6,  lanes 1-2 and 
8-9), as expected of the PAI-1 (2, 4,  14, 66) and fibronectin 
subunits (53). The Mr 54,000 band also appeared increased 
P611~nen  et al. Localization of Urokinase and Its Inhibitor  1089 Figure 3. Immunofluorescence localization of PAI-1 in (A and C) cultured HT-1080 sarcoma cells and (B and D) 2-HES fibroblasts. Fixation 
was with methanol in A and B. Cells were removed using method I in C and D. Indirect immunofluorescence, monoclonal clone 1 anti-PAI-1 
antibodies and TRITC-conjugated anti-mouse IgG were used. Note the lack of staining in strialike areas in the otherwise uniform staining 
under the cells in A and especially C and D. Bars,  10 I~m. in the contact area preparations from dexamethasone-treated 
fibroblasts with SDS-PAGE under reducing conditions, but 
not with SDS PAGE under nonreducing conditions. This ap- 
parent discrepancy is due to the fact that less total protein was 
undeliberately applied to the gel lane corresponding to fibro- 
blasts without dexamethasone electrophoresed under reduc- 
ing conditions, 
Zymographic and Reverse Zymographic Analysis 
of the Contact Area Preparations 
Molecular forms of the plasminogen activators present in the 
contact area preparations were investigated by SDS-PAGE 
under  nonreduced  conditions  followed by  casein-agarose 
zymography (Fig. 7). In the contact area preparations of liT- 
1080 cells (lanes 1 and 2), PA activity migrated as a well- 
defined band at Mr 50,000,  as expected of u-PA. Addition- 
ally, higher molecular mass forms of PAs were detected as 
a  smear of activity between Mr 70,000  and  100,000, with a 
distinctive band at the latter end. Dexamethasone slightly di- 
minished the PA activity in the preparations. All the PA ac- 
tivity in the preparations is u-PA,  in that preparations run 
through a  column of Sepharose coupled monoclonal anti- 
u-PA antibodies lost all their PA activity, while treatment in 
a similar anti-t-PA column had no effect on the PA activity 
pattern of the preparations (data not shown). This indicates 
that PAI-1 and u-PA form a complex in the preparation which 
dissociates partly during electrophoresis, in agreement with 
previous fndings (4).  The reason that the lysis zone is not 
continuous between positions corresponding to Mr 50,000 
and 100,000 can be ascribed to the fact that excess inhibitor 
migrates slightly behind uncomplexed u-PA, preventing lysis 
in  that position.  Virtually no PA  activity was  detected in 
fibroblast contact preparations using  this  method (lanes 3 
and 4); only after several days' exposure did a weak lysis ap- 
pear at Mr 50,000. Control gels lacking plasminogen showed 
no caseinolytic activity. 
Reverse casein agarose zymography was carried out to test 
for PA inhibiting activities (Fig. 8). Analysis of the contact 
area preparations of HT-1080 cells as well as fibroblasts re- 
vealed a major inhibitor zone at Mr 54,000. Dexamethasone 
markedly increased the intensity of the inhibitor zone of the 
HT-1080 contact area preparations (lanes 1 and 2), but this 
effect was  virtually non-existent in the fibroblast prepara- 
tions (lanes 3 and 4). 
Immunoblotting 
Contact area preparations of  dexamethasone-treated HT-1080 
cells were subjected to immunoblotting analysis under re- 
ducing conditions. The monoclonal PAI-1 antibody detected 
a  single band  at M~ 54,000  (Fig.  9,  lane 1).  Lane 2  is  a 
specificity control track immunoblotted with anti-TNP-IgG. 
Figure 4. Immunofluorescence localization of (A and B) u-PA and 
(C) PAI-I in HT-1080  cells. The cells were stained with the primary 
antibodies, (A and B) polyclonal rabbit anti-u-PA IgG, (C) mouse 
monoclonal anti-PAl-l, before fixation with methanol and incuba- 
tion with the secondary antibodies. The entire experiment was per- 
formed at 0°C. In A the focus is above the growth substratum at the 
cell-cell contacts and in B and C the microscope was focussed on 
the substratum. Bars, 10 ~tm. 
Ptll~inen et al. Localization of Urokinase and Its Inhibitor  1091 Figure 5. Double-immunofluorescence staining of methanol-fixed  HT-1080 cells for (,4) PAI-1 and (B) u-PA. The primary antibodies  were 
(A) mouse monoelonal anti-PAI-I and (B) polyclonal rabbit anti-u-PA IgG. The procedure is described in Materials  and Methods. Bars, 
10 ttm. 
Complexing of uSI-u-PA in Contact Area Preparations 
of  tqbroblasts 
When  uSI-u-PA (Mr  50,000,  Fig.  11,  lane a)  was added to 
preparations  obtained  from cultures  of 2-HES  fibroblasts 
using method I, and incubated for 60 min in the cold, a large 
proportion  of the  bound  label  was  converted  to  a  high 
molecular mass form: Mr 90,000 (Fig.  11, lane b). A  similar 
high molecular mass complex was obtained after incubation 
of t25I-u-PA with excess amounts of PAI-1 purified from the 
HT-1080 cell line (lane c). 
Discussion 
In the present  study we have described the distribution  of 
u-PA  and  an  Mr  54,000  PAI in  cultured  HT-1080  human 
fibrosarcoma cells and in human fibroblasts using both poly- 
clonal  and  specific  monoclonal antibodies.  In our experi- 
ments, u-PA was found to be located at discrete cellular con- 
tact sites under the fibrosarcoma cells, whereas its inhibitor 
was distributed as a homogeneously thick carpet on the sub- 
Figure 6. Macromolecular components of the contact area prepara- 
tions.  Metabolically  labeled  cells were extracted using the saponin 
procedure (method I), and the material  remaining  attached  to the 
glass coverslips was dissolved in Laemmli's sample buffer, 500 ~tl 
per coverslip. 70 I11 aliquots of  the samples were analyzed by 5-16% 
polyacrylamide gradient SDS PAGE under reducing (lanes  1-4) 
and nonreducing (lanes 5-9) conditions,  followed by autoradiogra- 
phy. The contact area preparations of  dexamethasone-treated  (lanes 
1 and 9) and untreated (lanes 2 and 8) HT-1080 cells, and dexameth- 
asone-treated  (lanes 3 and 7) and untreated  (lanes 4 and 6) 2-HES 
cells.  Lane 5: purified  radiolabeled  PAI-1. The molecular mass of 
the marker proteins  (reduced)  is shown in kilodaltons. 
Figure 7. Casein-agarose  zymography after 8% SDS PAGE of the 
contact area preparations.  70-gl samples of the contact area prepa- 
rations  of dexamethasone-treated  (lane  1) and untreated  (lane 2) 
HT-1080 cells,  and dexamethasone-treated  (lane  3) and untreated 
(lane 4) 2-HES cells were analyzed. Lane 5:250 mlU u-PA. Devel- 
opment at 37°C for 24 h. The positions of the Mr markers are indi- 
cated  in kilodaltons  on the right. 
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area preparations. 70-gl samples of the contact area preparations 
of dexamethasone-treated (lane 1) and untreated (lane 2) HT-1080 
cells, and dexamethasone-treated (lane 3) and untreated (lane 4) 
2-HES cells were analyzed. Development at 37°C for 24 h. The po- 
sitions of the Mr markers are indicated to the right in kilodaltons. 
stratum, but lacking in strialike areas. When live cells were 
stained, PAl-1 could not be detected under the central parts 
of the cells. Thus, we cannot exclude the possibilty that the 
negative strialike areas in saponin-treated cell preparations 
would be due to inaccessibility of the PAl-1 antigen to the an- 
tibodies used. At the electron microscopic level we detected 
patches  of anti-u-PA  staining  associated  with  the plasma 
membrane. This result, obtained by staining live cells in the 
cold with the primary antibody, indicated that u-PA on the 
cell surface is externally located. The deposition of fibronec- 
tin was also detected using a monoclonal antibody. Normal 
human  fibroblasts  showed low intensity of anti-u-PA  im- 
munoreactivity, while producing PA  inhibitor quite abun- 
dantly. 
Additional lines of  evidence were obtained, suggesting that 
u-PA and its inhibitor are indeed deposited to the contact 
areas of cells. First, the contact areas could be isolated with 
0.2 % saponin assisted mechanically with a stream of buffer. 
When such cell-free substrate-attached material,  prepared 
from [35S]methionine-labeled cells, was studied by fluorog- 
raphy, we found that an Mr 54,000 band was the major one 
in the preparations. This band includes PAl-l, as judged by 
immunoprecipitation experiments, although the presence of 
other proteins in the same position cannot be excluded. Still, 
its amount in the preparations was responsive to dexametha- 
sone treatment of the HT-1080  cell cultures in agreement 
with the previous findings (2, 4,  14, 53,  66).  PAl-1 in the 
contact area preparations could be immunoblotted with a 
specific monoclonal antibody. Apparently, u-PA is a  rela- 
tively minor component in the contact area preparations; we 
were unable to detect u-PA in these preparations using immu- 
noblotting. The PA activity of the contact area preparations 
was, however, confirmed with zymography which showed a 
major band  at Mr 50,000  as  well as  a  minor band  at Mr 
100,000.  Reverse zymography showed a  single Mr  54,000 
inhibitor in the preparations.  Furthermore, when 125I-u-PA 
was incubated with the preparations,  much of it was con- 
verted into a high molecular mass  form (Mr 90,000). This 
observation is consistent with the presence of PAI-1 in con- 
Figure 9. Immunoblotting of PA inhibitor under reduced conditions 
in a contact area preparation of dexamethasone-treated HT-1080 
contact area preparation,  using 50  gg/ml  monoclonal anti-PAI, 
clone 1 (lane 1 ) or monoclonal anti-TNP-IgG (lane 2). The posi- 
tions of the Mr markers are indicated in kilodaltons. 
tact area preparations, but further experiments are needed to 
determine whether the complexing of ~SI-u-PA is specifical- 
ly with PAId. 
The accessibility of u-PA for antibodies at the contact sites 
differed under various fixation and permeabilization condi- 
tions, methanol fixation at -20°C giving the clearest results. 
Even then, the monoclonal antibodies gave much less stain- 
ing than the polyclonal anti-u-PA antibodies we used. After 
removal of cells to obtain the contact area preparations both 
types of  antibodies gave a similar pattern of staining, suggest- 
ing that the determinant of the monoclonal antibody is re- 
strictedly exposed. 
The subcellular localization of u-PA has been previously 
explored by cell fractionation studies and by the immunocy- 
tochemical approach.  Despite conflicting results, there ap- 
pears to be a consensus among the various cell fractionation 
reports that PA activity is often localized in membrane-rich 
fractions. In Rous sarcoma virus-transformed chicken em- 
bryonal fibroblasts, u-PA has been localized to fractions con- 
taining the Golgi apparatus and the plasma membrane (57), 
whereas in growing and virus-transformed 3T3 cells exclu- 
sively to the plasma membrane-enriched fraction (28,  29). 
However, in a study of HT-1080 cells PA of non-determined 
type was  found associated  solely with  a  cellular fraction 
representing either the Golgi apparatus or secretory granules 
rather than plasma membrane (39). Interestingly, either u-PA 
or PA of nondetermined type from several cell lines includ- 
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itate of PAI-I from the contact area preparation of dexamethasone- 
treated HT-1080  cells. The cells were labeled for 2 h in medium con- 
taining 50 ~tCi/ml [35S]methionine. After extraction of cells, the 
labeled substrate-attached proteins were immunoprecipitated using 
monoclonal anti-PAid  (clone  1).  Lane 1:HT-1080 preparation; 
lane 2: the immunoprecipitate. 
ing HT-1080, has been found resistant to various solubiliza- 
tion procedures that would be expected to solubilize non- 
membrane integrated proteins (28, 39, 41, 43, 57, 69). As for 
the light microscopic studies the subcellular distribution of 
u-PA differs greatly in different cell types (38, 67). Only one 
study at the electron microscopic level PA (apparently u-PA) 
immunoreactivity has been reported to be associated with the 
cell membranes of porcine kidney cells (55). Furthermore, 
in two recent studies of  human monocyte-like U937 cells and 
peripheral blood monocytes (71, 79), u-PA was shown to bind 
with  its  noncatalytic  aminoterminal  domain  to  specific 
plasma membrane receptors, whereas the catalytic, carboxy- 
terminal domain remains exposed on the cell surface. Addi- 
tionally, Fibbi et al.  (21) have demonstrated the binding of 
a urokinase-ferritin conjugate to cell surface sites in A431 
human epidermoid carinoma cells and proposed that these 
represented single and clustered receptor. Our data fit well 
with the findings above. If indeed u-PA is bound to a receptor 
also in HT-1080 cells, the anti-u-PA immunoreactivity at the 
contact sites and on the plasma membrane (Fig. 2 A) could 
be based on local clustering of such receptors. 
Several different procedures have been used to isolate ma- 
terial designated either as cellular contact sites, cell substra- 
tum-attached material, foot pads, or focal contact membranes 
(5,  7,  9,  15,  37,  40,  47).  These procedures include use of 
chelating agents, low concentrations of nonionic or zwitter- 
ionic detergents, or mechanical extraction. All these proce- 
dures to  isolate the material from the growth  substratum 
should be considered operational only, because the material 
obtained  is  expected to  conulin both  extracellular matrix 
Figure 11. Complexing of radioiodinated urokinase (125I-u-PA, lane 
a) during incubation for 60 min at 4°C with contact area prepara- 
tions of 2-HES cells (lane b) and with excess amounts (about 100- 
fold with respect to u-PA) of purified PA inhibitor (lane c). The 
samples were analyzed in 8 % SDS PAGE  followed  by autoradiogra- 
phy. The positions of the Mr markers are indicated in kilodaltons 
(lane d). 
components and material binding from the culture medium 
to the glass  or plastic  surface, besides the actual cellular 
contact site components. Saponin, which we used as a cho- 
lesterol-removing detergent,  has  also been used to isolate 
acethylcholine receptor clusters from cultured rat myotubes 
(8).  In addition,  using  saponin and mechanical extraction 
Neyfakh et al. (47) found Mr 51,000 and 47,000 proteins in 
isolated focal contact membranes of mouse and chick fibro- 
blasts,  respectively. Interestingly, Bayley and Rees (7) de- 
tected a major new protein component with an Mr 50,000- 
55,000 in fibroblast focal adhesion preparations that remains 
attached to a glass substratum after cells are mechanically 
removed. Our results indicated that a contact area prepara- 
tion obtained by saponin treatment contains PAId. However, 
the inhibitor was not confned to discrete focal contacts, nor 
was it found to have a matrix-type distribution, instead it was 
found to be deposited under the ventral surface of the cells 
excluding strialike areas. 
Extracellular PA activity may be regulated at the level of 
cellular production and release of the activators themselves, 
and by modulators of the enzyme activity of the activators 
(for reviews, see references 16 and 59). Furthermore, the fact 
that PAs act as a part of a cascade reaction implies a more 
complicated set of control mecahnisms for the final proteo- 
lytic effect. Recent demonstration of proenyzmes with little 
or no activity (3,  17,  27,  32,  51,  67,  68,  82)  suggests that 
mechanisms, although at present unknown, exist that control 
the conversion of zymogens to active enzymes in the ex- 
tracellular space. Moreover, u-PA is inhibited by the abun- 
dant protease inhibitors of the human plasma, by the protease 
nexin, and by the recently reported more specific inhibitors 
(see our introductory text for references). Binding by pro- 
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u-PA. 
Our results demonstrating u-PA and PAI-1 in the contact 
area  preparations  add  a  novel  dimension  to  the  complex 
regulatory scenario of pericellular plasminogen activation. 
The protein concentration being too low in our preparations, 
we were not able to decide by immunoblotting, whether u-PA 
at the sarcoma cell contact sites is present as the one-chain 
inactive proenzyme.  The results obtained by zymography, 
demonstrating a PAI-1/u-PA  complex that is not formed by 
pro-u-PA (4), do not settle that question because pro-u-PA 
may have been activated during the zymography procedure. 
The difference in distribution between u-PA, being enriched 
into discrete contact sites, and PAI-1, being distributed as an 
extracellular carpet on the growth substratum,  could con- 
ceivably permit focal u-PA-mediated proteolysis to occur. 
The large amounts of the PAI on the growth substratum 
was a rather unexpected finding. This could be an indication 
of the need to secure the inhibition of PA in the pericellular 
area, to maintain cell surface integrity. Proteins bound in a 
similar way on to glass  substrata  include serum spreading 
factor  (vitronectin),  and the Mr  80,000  protein of serum- 
containing media (48). Vitronectin is an adhesive glycopro- 
tein that promotes spreading of a variety of cell types on cul- 
ture dishes (6, 24). The deposition of PAI-1 suggests that it 
may have functions other than enzyme inhibition. We are 
currently exploring this possibility. 
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